Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure · Other Events
Item 8.01. Other Events. On November 18, 2026, the Company received the Conditional Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that the deficiency relating to the minimum Market Value of Listed Securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) had been lifted because the Company had demonstrated compliance with the alternative mini…
Filed Nov 19, 2026Accepted Nov 19, 2026, 7:57 AM ESTCIK 1997296Accession 0001062993-26-006190
We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On November 18, 2026, the Company received the Conditional Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that the deficiency relating to the minimum Market Value of Listed Securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) had been lifted because the Company had demonstrated compliance with the alternative minimum shareholders' equity requirement of $2.5 million set forth in Nasdaq Listing Rule 5550(b)(1), giving effect to the completion of the transactions described in the Company's Current Report on Form 8-K filed with the SEC on November 16, 2026.
The Conditional Compliance Notice stated that the Company's compliance is conditioned upon the Company evidencing continued compliance with the minimum shareholders' equity requirement in its next periodic report for the period ending December 31, 2026. If the Company does not evidence compliance with the minimum shareholders' equity requirement in that report, the Company may be subject to delisting from Nasdaq.
There can be no assurance that the Company will be able to maintain compliance with the minimum shareholders' equity requirement, that Nasdaq will determine that the Company has satisfied the condition set forth in the Conditional Compliance Notice or that the Company will be able to maintain compliance with Nasdaq's other continued listing requirements in the future.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On November 19, 2026, the Company issued a press release regarding the matters described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.